Submitted:
07 February 2024
Posted:
08 February 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusion
Author Contributions
Ethical Considerations
Financing Statement
Acknowledgments
Conflicts of Interests
References
- Mlugu EM, Mohamedi JA, Sangeda RZ, Mwambete KD. Prevalence of urinary tract infection and antimicrobial resistance patterns of uropathogens with biofilm forming capacity among outpatients in morogoro, Tanzania: a cross-sectional study. BMC Infect Dis, 2023;23(1):660. [CrossRef] [PubMed]
- Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am, 2014 Mar;28(1):1-13. [CrossRef] [PubMed]
- Kaur R, Kaur R. Symptoms, risk factors, diagnosis and treatment of urinary tract infections. Postgrad Med J, 2021 Dec;97(1154):803-812. [CrossRef] [PubMed]
- Sobel JD, Kaye D. Host factors in the pathogenesis of urinary tract infections. Am J Med, 1984 May 15;76(5A):122-30. [CrossRef] [PubMed]
- Murray BO, Flores C, Williams C. Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems. Front Cell Infect Microbiol, 2021;11:691210. [CrossRef] [PubMed]
- Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol, 2018;219(1):40-51. [CrossRef] [PubMed]
- Lacerda Mariano L, Ingersoll MA. The immune response to infection in the bladder. Nat Rev Urol, 2020;17(8):439-458. [CrossRef] [PubMed]
- Clemens JQ. Infection and Inflammation of the Genitourinary Tract. J Urol, 2022;208(3):716-717. [CrossRef]
- Best J, Kitlowski AD, Ou D, Bedolla J. Diagnosis and management of urinary tract infections in the emergency department. Emerg Med Pract, 2014;16(7):1-24.
- Covino M, Manno A, Merra G, et al. Reduced utility of early procalcitonin and blood culture determination in patients with febrile urinary tract infections in the emergency department. Intern Emerg Med, 2020;15(1):119-125. [CrossRef]
- Guermazi-Toumi S, Boujlel S, Assoudi M, Issaoui R, Tlili S, Hlaiem ME. Susceptibility profiles of bacteria causing urinary tract infections in Southern Tunisia. J Glob Antimicrob Resist, 2018;12:48-52. [CrossRef]
- Jean SS, Coombs G, Ling T, et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. Int J Antimicrob Agents, 2016;47(4):328-334. [CrossRef] [PubMed]
- Gravey F, Loggia G, de La Blanchardière A, Cattoir V. Bacterial epidemiology and antimicrobial resistance profiles of urinary specimens of the elderly. Med Mal Infect, 2017;47(4):271-278. [CrossRef] [PubMed]
- Gormley EA. Recurrent urinary tract infection in women: emerging concepts regarding etiology and treatment considerations. Curr Urol Rep, 2003;4(5):399-403. [CrossRef]
- Ramírez F, Exeni A, Alconcher L, et al. Guía para el diagnóstico, estudio y tratamiento de la infección urinaria: actualización 2022 [Clinical practice guideline for the diagnosis and management of urinary tract infections: 2022 update]. Arch Argent Pediatr, 2022;120(5):S69-S87. [PubMed]
- Gonzalez CM, Schaeffer AJ. Treatment of urinary tract infection: what's old, what's new, and what works. World J Urol, 1999;17(6):372-382. [CrossRef] [PubMed]
- 17 –. https://www.pordata.pt/censos/resultados/emdestaque-beira+baixa-538.
- Hansen MA, Valentine-King M, Zoorob R, et al. Prevalence and predictors of urine culture contamination in primary care: A cross-sectional study. Int J Nurs Stud. 2022;134:104325. [CrossRef]
- Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49(2):53-70. [CrossRef] [PubMed]
- Ansaldi Y, Martinez de Tejada Weber B. Urinary tract infections in pregnancy. Clin Microbiol Infect. 2023;29(10):1249-1253. [CrossRef]
- Taghavi Zahedkalaei A, Kazemi M, Zolfaghari P, Rashidan M, Sohrabi MB. Association Between Urinary Tract Infection in the First Trimester and Risk of Preeclampsia: A Case-Control Study. Int J Womens Health. 2020;12:521-526. [CrossRef]
- Laari JL, Anab M, Jabong DP, Abdulai K, Alhassan AR. Maternal Age and Stage of Pregnancy as Determinants of UTI in Pregnancy: A Case of Tamale, Ghana. Infect Dis Obstet Gynecol. 2022;2022:3616028. [CrossRef]
- Rosana Y, Ocviyanti D, Halim M, et al. Urinary Tract Infections among Indonesian Pregnant Women and Its Susceptibility Pattern. Infect Dis Obstet Gynecol. 2020;2020:9681632. [CrossRef]
- Dube R, Al-Zuheiri STS, Syed M, Harilal L, Zuhaira DAL, Kar SS. Prevalence, Clinico-Bacteriological Profile, and Antibiotic Resistance of Symptomatic Urinary Tract Infections in Pregnant Women. Antibiotics (Basel). 2022;12(1):33. [CrossRef] [PubMed]
- Sabbuba NA, Mahenthiralingam E, Stickler DJ. Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol. 2003;41(11):4961-4965. [CrossRef] [PubMed]
- Clarke K, Hall CL, Wiley Z, et al. Catheter-Associated Urinary Tract Infections in Adults: Diagnosis, Treatment, and Prevention. J Hosp Med. 2020;15(9):552-556. [CrossRef] [PubMed]
- Gauron G, Bigand T. Implementation of evidence-based strategies to reduce catheter-associated urinary tract infections among hospitalized, post-surgical adults. Am J Infect Control. 2021;49(6):843-845. [CrossRef] [PubMed]
- Fink R, Gilmartin H, Richard A, Capezuti E, Boltz M, Wald H. Indwelling urinary catheter management and catheter-associated urinary tract infection prevention practices in Nurses Improving Care for Healthsystem Elders hospitals. Am J Infect Control. 2012;40(8):715-720. [CrossRef]
- Foong KS, Munigala S, Jackups R Jr, Yarbrough ML, Burnham CA, Warren DK. Incidence and Diagnostic Yield of Repeat Urine Culture in Hospitalized Patients: an Opportunity for Diagnostic Stewardship. J Clin Microbiol. 2019;57(10):e00910-19. [CrossRef]
- Ganzeboom KMJ, Uijen AA, Teunissen DTAM, et al. Urine cultures and antibiotics for urinary tract infections in Dutch general practice. Prim Health Care Res Dev. 2018;20:e41. [CrossRef]
- Shimoni Z, Avdiaev R, Froom P. Urine Cultures in Hospitalized Geriatric Patients Presenting With Fever. Am J Med Sci. 2017;353(1):17-21. [CrossRef] [PubMed]
- Piñeiro Pérez R, Cilleruelo Ortega MJ, Ares Álvarez J, et al. Recomendaciones sobre el diagnóstico y tratamiento de la infección urinaria [Recommendations on the diagnosis and treatment of urinary tract infection]. An Pediatr (Engl Ed). 2019;90(6):400.e1-400.e9. [CrossRef]
- Al-Mendalawi MD. Antibiotic resistance pattern and empirical therapy for urinary tract infections in children. Saudi Med J. 2008;29(10):1520.
- Gökçe İ, Çiçek N, Güven S, et al. Changes in Bacterial Resistance Patterns of Pediatric Urinary Tract Infections and Rationale for Empirical Antibiotic Therapy. Balkan Med J. 2017;34(5):432-435. [CrossRef]
- Bhowmik D, Singh S. Complicated urinary tract infections. J Indian Med Assoc. 2013;111(8):545-549. [PubMed]
- Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health. 2009;2(3):101-111. [CrossRef]
- Muder RR, Brennen C, Rihs JD, et al. Isolation of Staphylococcus aureus from the urinary tract: association of isolation with symptomatic urinary tract infection and subsequent staphylococcal bacteremia. Clin Infect Dis. 2006;42(1):46-50. [CrossRef] [PubMed]
- Kot B. Antibiotic Resistance Among Uropathogenic Escherichia coli. Pol J Microbiol. 2019;68(4):403-415. [CrossRef]
- Moreira da Silva RCR, de Oliveira Martins Júnior P, Gonçalves LF, et al. Ciprofloxacin resistance in uropathogenic Escherichia coli isolates causing community-acquired urinary infections in Brasília, Brazil. J Glob Antimicrob Resist. 2017;9:61-67. [CrossRef]
- Gobernado M, Valdés L, Alós JI, et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimioter. 2007;20(1):68-76. Rev Esp Quimioter.
- López-Sampedro I, Hernández-Chico I, Gómez-Vicente E, Expósito-Ruiz M, Navarro-Marí JM, Gutiérrez-Fernández J. Evolution of Antibiotic Resistance in Escherichia coli and Klebsiella pneumoniae from Urine Cultures. Arch Esp Urol. 2023;76(3):203-214. [CrossRef]
- Oteo J, Delgado-Iribarren A, Vega D, et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents. 2008;32(6):534-537. [CrossRef]
- Hayakawa K, Matsumura Y, Uemura K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2023;67(10):e0051023. [CrossRef]
- Zhang X, Zhang Y, Wang F, et al. Unravelling mechanisms of nitrofurantoin resistance and epidemiological characteristics among Escherichia coli clinical isolates. Int J Antimicrob Agents. 2018;52(2):226-232. [CrossRef]
- Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother. 2008;62(3):495-503. [CrossRef]
- Mahdizade Ari M, Dashtbin S, Ghasemi F, et al. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. Front Cell Infect Microbiol. 2023;13:1148603. Published 2023 Jul 27. [CrossRef]
- Zhong ZX, Cui ZH, Li XJ, et al. Nitrofurantoin Combined With Amikacin: A Promising Alternative Strategy for Combating MDR Uropathogenic Escherichia coli. Front Cell Infect Microbiol. 2020;10:608547. Published 2020 Dec 21. [CrossRef]
- Abavisani M, Bostanghadiri N, Ghahramanpour H, et al. Colistin resistance mechanisms in Gram-negative bacteria: a Focus on Escherichia coli. Lett Appl Microbiol. 2023;76(2):ovad023. [CrossRef]
- Anyanwu MU, Jaja IF, Okpala COR, Njoga EO, Okafor NA, Oguttu JW. Mobile Colistin Resistance (mcr) Gene-Containing Organisms in Poultry Sector in Low- and Middle-Income Countries: Epidemiology, Characteristics, and One Health Control Strategies. Antibiotics (Basel). 2023;12(7):1117. [CrossRef]
- Hatlen TJ, Flor R, Nguyen MH, Lee GH, Miller LG. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020;75(7):1993-1997. [CrossRef]
- Burgos RM, Rodvold KA. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections. Future Microbiol. 2019;14:461-475. [CrossRef]
- Rodrigues D, Baldissera GS, Mathos D, Sartori A, Zavascki AP, Rigatto MH. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity. Braz J Microbiol. 2021;52(4):1913-1919. [CrossRef] [PubMed]
- Ballén V, Gabasa Y, Ratia C, Ortega R, Tejero M, Soto S. Antibiotic Resistance and Virulence Profiles of Klebsiella pneumoniae Strains Isolated From Different Clinical Sources. Front Cell Infect Microbiol. 2021;11:738223. [CrossRef] [PubMed]
- Urbaniec J, Getino M, McEwan TB, et al. Anti-persister efficacy of colistin and meropenem against uropathogenic Escherichia coli is dependent on environmental conditions. Microbiology (Reading). 2023;169(11). [CrossRef] [PubMed]




| Escherichia coli | 2018 | 2019 | 2020 | 2021 | 2022 |
| Ampicillin | |||||
| 48,7% | 49,3% | 46,1% | NA | NA | |
| Amoxicillin | |||||
| NA | NA | NA | 0% | NA | |
| Amoxicillin/ Clavulanic Acid | |||||
| 36,2% | 41,8% | 37,3% | 35% | 32,6% | |
| Piperacillin/Tazobactam | |||||
| 6,3% | 7,2% | 6,3% | NA | NA | |
| Cefuroxime Axetil | |||||
| 20,6% | 18,0% | 16,0% | 14,6% | 18,2% | |
| Cefotaxim3 | |||||
| 13,1% | 11,6% | 11% | NA | NA | |
| Ceftazidime | |||||
| 13,1% | 7,5% | 6,8% | NA | NA | |
| Ceftazidime/Avibactam | |||||
| NA | NA | NA | 4,8% | 7,2% | |
| Cefepime | |||||
| 12,8% | 4,6% | 5,2% | NA | NA | |
| Gentamicin | |||||
| 8,3% | 10,2% | 6,1% | NA | NA | |
| Amikacin | |||||
| 0% | 0,4% | 0,4% | NA | NA | |
| Ciprofloxacin | |||||
| 23,1% | 24,2% | 20,6% | NA | NA | |
| Nitrofurantoin | |||||
| 0,8% | 2,0% | 0,9% | 20,4% | 24,4% | |
| Fosfomycin | |||||
| 1,4% | 3,6% | 2,0% | NA | NA | |
| Trimethoprim/Sulfamethoxazole | |||||
| 27,7% | 28,7% | 24,2% | 24,3% | 26,7% | |
| Meropenem | |||||
| 0,1% | 0,1% | 0% | NA | NA | |
| Ertapenem | |||||
| 0,4% | 0,1% | 0,1% | 0,1% | 0,0% | |
| Colistin | |||||
| 0,1% | 0,3% | 1,5% | NA | NA | |
| Klebsiella pneumoniae | 2018 | 2019 | 2020 | 2021 | 2022 |
| Ampicillin | |||||
| 26,8% | 37,4% | 35,8% | NA | NA | |
| Amoxicillin | |||||
| NA | NA | NA | 100% | 100% | |
| Amoxicillin/Clavulanic Acid | |||||
| 41,0% | 51,8% | 47,5% | 38,5% | 35,8% | |
| Piperacillin/Tazobactam | |||||
| 20,9% | 20,6% | 19,5% | NA | NA | |
| Cefuroxime Axetil | |||||
| 30,9% | 39,4% | 35,7% | 22,1% | 24,6% | |
| Cefotaxime | |||||
| 23,0% | 35,3% | 32,8% | NA | ||
| Ceftazidime | |||||
| 23,6% | 35,7% | 30,7% | 100,0% | 100,0% | |
| Clotrimazole | |||||
| 100,0% | 100,0% | ||||
| Cefepime | |||||
| 23,0% | 28,1% | 19,7% | |||
| Gentamicin | |||||
| 18,5% | 29,7% | 24,8% | |||
| Amikacin | |||||
| 3,9% | 2,4% | 1,3% | 100,0% | 100,0% | |
| Ciprofloxacin | |||||
| 25,3% | 41,8% | 37,4% | |||
| Nitrofurantoin | |||||
| 18,5% | 18,2% | 100,0% | 27,2% | 25,9% | |
| Fosfomycin | |||||
| 19,1% | 21,7% | 21,0% | 33,3% | 7,7% | |
| Trimethoprim/Sulfamethoxazole | |||||
| 27,0% | 34,5% | 27,7% | 24,1% | 22,8% | |
| Meropen | |||||
| 40,0% | 26,7% | 33,3% | |||
| Ertapenem | |||||
| 2,8% | 3,6% | 3,8% | 4,3% | 4,3% | |
| Colistin | |||||
| 0,0% | 0,4% | 0,8% | |||
| Metronidazole | |||||
| 100,0% | 100,0% | ||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).